Core biological marker candidates of Alzheimer's disease - perspectives for diagnosis, prediction of outcome and reflection of biological activity.
about
The past and the future of Alzheimer's disease CSF biomarkers-a journey toward validated biochemical tests covering the whole spectrum of molecular eventsUpdate on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease.Cerebrospinal fluid biomarkers of Alzheimer's disease.Recent cerebrospinal fluid biomarker studies of Alzheimer's disease.Cerebrospinal fluid abnormalities and rate of decline in everyday function across the dementia spectrum: normal aging, mild cognitive impairment, and Alzheimer disease.Alzheimer's disease: a healthcare burden of epidemic proportion.Biomarkers in Alzheimer's disease.Does CSF p-tau181 help to discriminate Alzheimer's disease from other dementias and mild cognitive impairment? A meta-analysis of the literature.Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeuticsWays toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI).Genomic characterization of Alzheimer's disease and genotype-related phenotypic analysis of biological markers in dementia.Toward biomarkers in multiple sclerosis: new advances.Proteomics of Alzheimer's disease: understanding mechanisms and seeking biomarkers.Primary prevention and delay of onset of AD/dementia.Mass spectrometry-based proteomics and peptidomics for biomarker discovery in neurodegenerative diseasesBiomarkers for early diagnosis of Alzheimer disease: 'ALZheimer ASsociated gene'--a new blood biomarker?Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease.Tau-based treatment strategies in neurodegenerative diseasesBiomarkers for Alzheimer disease in cerebrospinal fluid, urine, and blood.Cerebrospinal fluid biomarkers of Alzheimer's disease in healthy elderly.The development of effective biomarkers for Alzheimer's disease: a review.Etiology and pathogenesis of late-onset Alzheimer's disease.Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseases-From pathophysiology to clinical practice.Tau as a biomarker of neurodegenerative diseases.Mild cognitive impairment should be considered for DSM-V.Optical imaging of the rat brain suggests a previously missing link between top-down and bottom-up nervous system function.Current Approaches and Clinician Attitudes to the Use of Cerebrospinal Fluid Biomarkers in Diagnostic Evaluation of Dementia in Europe.Correlations between mini-mental state examination score, cerebrospinal fluid biomarkers, and pathology observed in brain biopsies of patients with normal-pressure hydrocephalus.Antipsychotic medication is associated with selective alterations in ventricular cerebrospinal fluid Aβ 40 and tau in patients with intractable unipolar depression.Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia.High CSF Tau-protein concentration in delirium induced by high dose psychiatric medication.Unraveling the role of metal ions and low catalytic activity of cytochrome C oxidase in Alzheimer's disease.Effective Theranostic Cyanine for Imaging of Amyloid Species in Vivo and Cognitive Improvements in Mouse Model
P2860
Q26781635-53D2AE9B-D80B-4157-B373-01063CA5B137Q30845482-529C0226-DAED-4561-B789-E7FAB4EA2A2CQ33757828-8D8F20BD-043F-41B3-B443-28517930D9E6Q33766323-9BFA7FE0-1D1E-45C2-BCEB-D4FE37E24D56Q33924646-899D606E-FEBB-4379-A6F4-D7CE51F5640BQ33932371-B37750E4-7E0B-4A1C-848B-33FEB91493D1Q35113795-1009B40F-5782-40B4-8404-196FA0701012Q35166684-4D6F6CFD-0423-4EA6-88E3-925C9425D0E7Q35649302-61D5AAF3-BADB-44B0-A367-78E5A2B2A1B5Q35781558-53B7B901-1F68-4042-8EA7-1E19DE2ECFEEQ35976397-AED31B0C-1446-4568-9D11-437A5EC55931Q36492380-7A6A4F02-A290-4D73-9FBD-411889918341Q36787240-F2FCA930-CA2E-431E-BEE4-BB858F7B4E99Q36806653-ACAB55A2-FC78-417C-AFA7-D56ABAE68E88Q36974613-36252818-6381-49FF-B7F9-1CAEDAF4EDFFQ37118083-C827CA6F-83EE-4095-90C5-D0527BDAF4B0Q37181302-3F21DE8B-F5C9-4F47-9E48-4336F688226EQ37215861-5D2445C1-B105-4717-8A39-A7B117E514DBQ37273675-39850DA4-D80B-4AAC-A7F5-D4BDEB43D28AQ37524486-8CE8F22E-8180-41DD-811D-803374F57274Q38016800-2D8510BA-EC9D-4352-A0A8-D80E0EDFD603Q38178837-D37B1668-1BD9-498B-A433-BE861172B9DCQ38825497-D987CD3B-A86D-4FC8-AB04-FBA41F88498EQ40065021-9A32AFB3-F658-4F78-A4F4-9E2B2F7317D9Q40301859-7A0061DB-C9F8-4DA9-9EBF-5923FD00F300Q47290007-94BAFD40-715E-491B-9335-FA5F53480231Q47641756-4BFBCEEC-598F-47F0-A539-477993530EBCQ48232658-F30D71AD-B571-4B7A-9692-8D642E00D08BQ48913533-BF9057CB-828D-4829-AF6C-AFB3616329D3Q51972716-5B897E6D-B2DA-46BC-ABB5-7D525C11BE4FQ53281971-B14ED423-2B71-440B-BCA2-F485C4D45FF9Q53312216-41DC0AC6-4132-49C7-AB4D-056BB6E7D780Q58376424-7B8F0579-9BF7-4D58-888C-BB0ECDB572EB
P2860
Core biological marker candidates of Alzheimer's disease - perspectives for diagnosis, prediction of outcome and reflection of biological activity.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Core biological marker candida ...... ection of biological activity.
@ast
Core biological marker candida ...... ection of biological activity.
@en
type
label
Core biological marker candida ...... ection of biological activity.
@ast
Core biological marker candida ...... ection of biological activity.
@en
prefLabel
Core biological marker candida ...... ection of biological activity.
@ast
Core biological marker candida ...... ection of biological activity.
@en
P2093
P1476
Core biological marker candida ...... ection of biological activity.
@en
P2093
A Mitchell
H-J Möller
S Brettschneider
P2888
P304
P356
10.1007/S00702-003-0065-Z
P50
P577
2003-12-03T00:00:00Z